152 related articles for article (PubMed ID: 3622306)
1. Influence of cyclandelate on in vitro red blood cell deformability.
Hall DW; van den Hoven WE
Drugs; 1987; 33 Suppl 2():30-40. PubMed ID: 3622306
[TBL] [Abstract][Full Text] [Related]
2. Calcium modulation and clinical effect. Profile of cyclandelate.
Timmerman H
Drugs; 1987; 33 Suppl 2():1-4. PubMed ID: 3622303
[TBL] [Abstract][Full Text] [Related]
3. The influence of cyclandelate on Ca++ translocation in human platelets.
Akkerman JW; van den Hoven WE
Drugs; 1987; 33 Suppl 2():53-9. PubMed ID: 3622308
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human platelet functions by cyclandelate.
van den Hoven WE; Hall DW
Drugs; 1987; 33 Suppl 2():41-52. PubMed ID: 3304954
[TBL] [Abstract][Full Text] [Related]
5. Effect of cyclandelate on prostacyclin release and cytosolic free calcium concentrations in human endothelial cells.
van Hinsbergh VW
Drugs; 1987; 33 Suppl 2():60-6. PubMed ID: 3304955
[TBL] [Abstract][Full Text] [Related]
6. Cyclandelate as a calcium modulating agent in rat cerebral cortex.
Bast A; Leurs R; Timmerman H
Drugs; 1987; 33 Suppl 2():67-74. PubMed ID: 3040372
[TBL] [Abstract][Full Text] [Related]
7. Red blood cell deformability in diabetes mellitus: effect of phytomenadione.
Sabo A; Jakovljević V; Stanulović M; Lepsanović L; Pejin D
Int J Clin Pharmacol Ther Toxicol; 1993 Jan; 31(1):1-5. PubMed ID: 8444511
[TBL] [Abstract][Full Text] [Related]
8. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication.
Dawson DL; Zheng Q; Worthy SA; Charles B; Bradley DV
Angiology; 2002; 53(5):509-20. PubMed ID: 12365857
[TBL] [Abstract][Full Text] [Related]
9. The role of pentoxifylline in endotoxin-induced alterations of red cell deformability and whole blood viscosity in the neonate.
Mollitt DL; Poulos ND
J Pediatr Surg; 1991 May; 26(5):572-4. PubMed ID: 2061813
[TBL] [Abstract][Full Text] [Related]
10. Cyclandelate: calcium modulation and clinical effects. Proceedings of a symposium. Helsinki, 14-15 November, 1986.
Drugs; 1987; 33 Suppl 2():1-141. PubMed ID: 3622302
[No Abstract] [Full Text] [Related]
11. Cyclandelate. An inhibitor of cholesterol esterification.
Middleton B; Cacciaguerra F; White D
Drugs; 1987; 33 Suppl 2():75-9. PubMed ID: 3622309
[TBL] [Abstract][Full Text] [Related]
12. [Effect of alcoholic hyperlipoproteinemias on the deformability and viscosity of erythrocytes].
Goebel KM; Goebel FD; Lanser KG
Schweiz Med Wochenschr; 1984 Oct; 114(40):1386-8. PubMed ID: 6494873
[TBL] [Abstract][Full Text] [Related]
13. Cyclandelate and a number of its metabolites inhibit discocyte-echinocyte transformations of human erythrocytes.
Van den Hoven WE; Hall DW; Burns JW
Br J Clin Pract Suppl; 1984; 34():26-30. PubMed ID: 6430318
[No Abstract] [Full Text] [Related]
14. The effect of flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment.
Kavanagh BD; Coffey BE; Needham D; Hochmuth RM; Dewhirst MW
Br J Cancer; 1993 Apr; 67(4):734-41. PubMed ID: 8471430
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory action of cyclandelate and a number of its metabolites on cyclic AMP phosphodiesterase.
Van den Hoven WE; Hall DW; Burns JW
Br J Clin Pract Suppl; 1984; 34():20-5. PubMed ID: 6331483
[No Abstract] [Full Text] [Related]
16. Reduced red cell deformability associated with blood flow and platelet activation: improved by dipyridamole alone or combined with aspirin.
Bozzo J; Hernández MR; Ordinas A
Cardiovasc Res; 1995 Nov; 30(5):725-30. PubMed ID: 8595619
[TBL] [Abstract][Full Text] [Related]
17. Modes and mechanisms of action of vasoactive drugs and especially of cyclandelate.
Timmerman H
Br J Clin Pract Suppl; 1984; 34():10-9. PubMed ID: 6430317
[No Abstract] [Full Text] [Related]
18. Inhibition of aldose reductase from rat nervous tissue by metabolites of cyclandelate.
Van den Hoven WE; Hall DW; Burns JW
Br J Clin Pract Suppl; 1984; 34():31-3. PubMed ID: 6430320
[No Abstract] [Full Text] [Related]
19. Role molecular signaling pathways in changes of red blood cell deformability.
Muravyov AV; Tikhomirova IA
Clin Hemorheol Microcirc; 2013; 53(1-2):45-59. PubMed ID: 22951624
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human platelet aggregation by cyclandelate.
Van den Hoven WE; Hall DW
Br J Clin Pract Suppl; 1984; 34():34-8. PubMed ID: 6430321
[No Abstract] [Full Text] [Related]
[Next] [New Search]
